Anti-sRANKL antibody (ab62516)
Key features and details
- Rabbit polyclonal to sRANKL
- Suitable for: WB, IHC-P
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
Overview
-
Product name
Anti-sRANKL antibody
See all sRANKL primary antibodies -
Description
Rabbit polyclonal to sRANKL -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide (Human) of 14 amino acids from near the centre of sRANKL
-
General notes
This antibody will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
pH: 7.2
Preservative: 0.02% Sodium azide
Constituent: PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab62516 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | Use a concentration of 0.25 - 0.5 µg/ml. Detects a band of approximately 30 kDa (predicted molecular weight: 35 kDa). | |
| IHC-P | Use a concentration of 5 µg/ml. |
Target
-
Function
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. -
Tissue specificity
Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. -
Involvement in disease
Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Post-translational
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17. -
Cellular localization
Cytoplasm; Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8600 Human
- Entrez Gene: 21943 Mouse
- Entrez Gene: 117516 Rat
- Omim: 602642 Human
- SwissProt: O14788 Human
- SwissProt: O35235 Mouse
- SwissProt: Q9ESE2 Rat
- Unigene: 333791 Human
see all -
Alternative names
- CD254 antibody
- hRANKL2 antibody
- ODF antibody
see all
Images
-
Western blot - Anti-sRANKL antibody (ab62516)All lanes : Anti-sRANKL antibody (ab62516) at 1 µg/ml
Lane 1 : A431 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) cell lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution
Predicted band size: 35 kDa -
Western blot - Anti-sRANKL antibody (ab62516)All lanes : Anti-sRANKL antibody (ab62516) at 2 µg/ml
Lane 1 : Mouse kidney tissue lysate
Lane 2 : Mouse skin tissue lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat anti-rabbit IgG HRP conjugate at 1/10000 dilution
Predicted band size: 35 kDa -
Western blot - Anti-sRANKL antibody (ab62516)Lane 1 : Anti-sRANKL antibody (ab62516) at 0.25 µg/ml
Lane 2 : Anti-sRANKL antibody (ab62516) at 0.5 µg/ml
All lanes : rat liver tissue lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 35 kDa
Observed band size: 30 kDa why is the actual band size different from the predicted? -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-sRANKL antibody (ab62516)Immunohistochemical analysis of RANKL expression in paraffin embedded human liver tissue using 5 µg/ml ab62516
Protocols
Datasheets and documents
References (14)
ab62516 has been referenced in 14 publications.
- Gama A et al. Origins of Alterations to Rankl Null Mutant Mouse Dental Root Development. Int J Mol Sci 21:N/A (2020). PubMed: 32209985
- Shu Q et al. Mechanisms by which electroacupuncture-mediated histone acetylation mitigates bone loss in rats with ovariectomy-induced osteoporosis. Mol Med Rep 22:3453-3463 (2020). PubMed: 32945471
- Ock S et al. RANKL blockade suppresses pathological angiogenesis and vascular leakage in ischemic retinopathy. Biochem Biophys Res Commun 516:350-356 (2019). PubMed: 31208720
- Hiyama S et al. Osteoclastogenesis from bone marrow cells during estrogen-induced medullary bone formation in Japanese quails. J Mol Histol 50:389-404 (2019). PubMed: 31214852
- Tao YW et al. Association between Increased Inducible Costimulator/Inducible Costimulator Ligand Expression with Bone Destruction in Apical Periodontitis. J Endod 45:890-897 (2019). PubMed: 31153660
